Biond Biologics and GIBF close $8M China JV to advance BND-67 and BND-22. Phase 1 for BND-67 starts Q2 2026. BND-22 Phase 2 data from MD Anderson is the next catalyst.
Alpha Score of 34 reflects weak overall profile with weak momentum, poor value, moderate quality, moderate sentiment.
Biond Biologics Ltd. and the Guangzhou-Israel Biotechnology Fund (GIBF) closed an $8 million investment and formed a China-based joint venture on June 1, 2026. The deal targets the advancement of Biond's oncology pipeline inside the Chinese market. The joint venture will focus on pushing forward BND-67, a first-in-class therapy targeting CD28 shedding, and BND-22, a Phase 2 anti-ILT2 antibody, among other assets.
This structure allows GIBF to provide capital directly, while bringing regulatory guidance and local operational capabilities for Biond's clinical programs. GIBF is a life science investment fund focused on helping global biotech companies access China's market infrastructure.
BND-67 is Biond's next-generation immunotherapy targeting CD28 shedding, a novel immune evasion mechanism. The drug is designed to preserve CD28 signaling, which enhances effector T-cell activity while selectively inhibiting regulatory T-cell function. That mechanism could offer a fundamentally different approach compared to conventional checkpoint inhibitors. The program is IND-ready, with a Phase 1 trial planned for Q2 2026.
Given the central role of CD28 in T-cell activation, BND-67 introduces a new approach to restoring immune responsiveness. The expected timing for Phase 1 puts the first human data roughly 12 months from the announcement.
BND-22 is a Phase 2 anti-ILT2 checkpoint inhibitor designed to target the ILT2-HLA-G axis. Biond has reported efficacy in heavily treated cancer patients, including indications that are traditionally difficult for immuno-oncology therapies, such as MSS-CRC. The drug is currently being evaluated in an ongoing Phase 2 study at MD Anderson Cancer Center.
A Phase 2 readout from MD Anderson could serve as a key catalyst over the next 12-to-18 months. If the data supports the early signal, it could strengthen the JV's negotiating position for combination strategies and local partnerships.
The joint venture puts Biond's pipeline into a legal entity based in China, with GIBF providing local clinical development, regulatory strategy, and collaborations. The structure allows Biond to access China's biotech market without building its own local footprint from scratch.
Biond and GIBF aim to accelerate clinical execution, expand combination strategies, and maximize the pipeline's value in the Chinese market. GIBF's managing partner Avner Lushi stated that the fund's unique investment model would enable efficient asset advancement and that the partners are seeking additional collaborations across Asia.
This deal de-risks Biond's China strategy, at least at the operational level, since the local partner assumes the regulatory and execution risk inside the country.
What this means: The JV reduces Biond's capital needs and local execution risk. It does not reduce clinical or regulatory risk. The next concrete milestones are BND-67 Phase 1 initiation in Q2 2026 and any interim BND-22 data from MD Anderson.
For a private clinical-stage company, this JV provides capital and market access without a full public offering. The deal's size is modest at $8 million. The operational leverage from the GIBF partnership could be significant if either program produces strong data. The next 18 months will determine whether the CD28 shedding thesis translates into patient benefit.
Prepared with AlphaScala editorial tooling from the source reporting linked above. Indexable analysis may include a cited Alpha Score value. Publishing checks screen each story before release. Educational coverage, not personalized advice.